X0306 4 2015-07-13 0 0001404281 Tokai Pharmaceuticals Inc TKAI 0001297709 Novartis Bioventures Ltd 131 FRONT STREET HAMILTON D0 HM 12 BERMUDA 0 0 1 0 0001114448 NOVARTIS AG LICHTSTRASSE 35 BASEL V8 4056 SWITZERLAND 0 0 1 0 Common Stock 2015-07-13 4 S 0 20611 14.202 D 4524885 D Common Stock 2015-07-14 4 S 0 27861 14.41 D 4497024 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.20 to $14.215, inclusive. The reporting persons undertake to provide to Tokai Pharmaceuticals Inc., any security holder of Tokai Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. These shares are directly owned by Novartis BioVentures Ltd. Novartis BioVentures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.20 to $14.71, inclusive. The reporting persons undertake to provide to Tokai Pharmaceuticals Inc., any security holder of Tokai Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. /s/ Michael Jones, Director and /s/ Laurieann Chaikowsky, Authorized Signatory of Novartis BioVentures Ltd. 2015-07-15 /s/ Michael Jones, by Power of Attorney on behalf of Novartis AG; and /s/ David Middleton by Power of Attorney on behalf of Novartis AG 2015-07-15